Federal Circuit Partly Reverses Injunction In Equivalents Case

Mealey's (May 22, 2017, 2:18 PM EDT) -- WASHINGTON, D.C. — Although a Texas federal judge erred in barring the manufacture and sale of an accused generic form of the lymph-node-mapping dye isosulfan blue (ISB) with regard to two patents, relief was proper with regard to a third patent, the Federal Circuit U.S. Court of Appeals ruled May 19 (Mylan Institutional LLC, et al. v. Aurobindo Pharma Ltd., No. 17-1645, Fed. Cir., 2017 U.S. App. LEXIS 8792)....

Attached Documents

Related Sections